Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT04621955 Withdrawn - Multiple Myeloma Clinical Trials

Observational Study of Home Administration of Carfilzomib

KARE-2
Start date: June 2017
Phase:
Study type: Observational

The purpose of this study is to evaluate the feasibility of an at home administration program for carfilzomib patients.

NCT ID: NCT04584307 Withdrawn - Multiple Myeloma Clinical Trials

Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant

Immuno-POWER
Start date: April 2021
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to examine the role of an immune modulatory drug (IMID) in combination with elotuzumab, in a lenalidomide-free approach to maintenance therapy following second unplanned autologous peripheral blood stem cell transplant (PBSCT) for relapsed multiple myeloma.

NCT ID: NCT04467281 Withdrawn - Multiple Myeloma Clinical Trials

A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

Start date: June 30, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if using the radioactive tracer 89Zr-DFO-daratumumab with PET/CT scans is a practical and effective way to view and monitor multiple myeloma in participants before and during their treatment with daratumumab. We also want to see if 89Zr-DFO-daratumumab PET/CT scans can predict a participant's response to therapy, and if they can better locate any leftover disease following treatment compared to the standard imaging methods.

NCT ID: NCT04466475 Withdrawn - Plasma Cell Myeloma Clinical Trials

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Start date: January 27, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma. The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody, called OKT10-B10, linked to a radioactive substance called 211At. OKT10-B10 attaches to CD38 positive cancer cells in a targeted way and delivers 211At to kill them. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving 211At-OKT10-B10 with melphalan before a stem cell transplant may kill more cancer cells.

NCT ID: NCT04464889 Withdrawn - Multiple Myeloma Clinical Trials

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Start date: July 2, 2020
Phase: Phase 1
Study type: Interventional

This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent hematologic malignancies after allogeneic hematopoietic stem cell transplantation. The aim of the study is to determine the recommended phase II dose of MDG1021.

NCT ID: NCT04439305 Withdrawn - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Start date: February 25, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose cancer has a genetic change called DDR2 mutation. Dasatinib may block proteins called tyrosine kinases, which may be needed for cancer cell growth. Researchers hope to learn if dasatinib will shrink this type of cancer or stop its growth.

NCT ID: NCT04392648 Withdrawn - Clinical trials for Relapsed and/or Refractory Multiple Myeloma

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Start date: June 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of TAK-573 when used with dexamethasone and in combination with bortezomib, pomalidomide, or cyclophosphamide, in participants with RRMM.

NCT ID: NCT04361851 Withdrawn - Multiple Myeloma Clinical Trials

Study of Dara-Pembro for Multiple Myeloma Patients

Start date: June 9, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, single-arm, open-label study in subjects with relapsed and/or refractory multiple myeloma (RRMM) comparing Pembrolizumab (Pembro) in combination with Daratumumab (Dara) to the historical control of Daratumumab.

NCT ID: NCT04355039 Withdrawn - Clinical trials for Refractory Multiple Myeloma

INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, single-center, open-label phase Ib study aimed at determining a recommended phase II dose of INCB053914 and pomalidomide with dexamethasone. The trial will follow a 3 + 3 phase I dose-escalation design.

NCT ID: NCT04348006 Withdrawn - Clinical trials for Newly Diagnosed Multiple Myeloma

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

MM
Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.